Linked Life Data

17879158

Source:http://linkedlifedata.com/resource/pubmed/id/17879158

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-7-9
pubmed:abstractText
Purpose This multicenter phase II study examined the impact of pathological effect on survival after preoperative chemotherapy in Japanese women with early stage breast cancer. Patients and methods Prior to surgery, patients received four cycles of FEC (fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), cyclophosphamide 500 mg/m(2) q3w) followed by four cycles of docetaxel (75 mg/m(2) q3w). Primary endpoint was 3 year disease free survival (DFS) stratified by the absence or presence of Quasi-pCR (QpCR; absence of invasive tumor or only focal residual tumor cells). Secondary endpoints were predictors for QpCR, clinical response, breast conservation rate, and safety. Results Between June 2002 and June 2004, 202 women were enrolled. Among 191 assessable patients, 25% achieved QpCR. With 40 months median follow-up, 3 year DFS was estimated at 91% for all patients. 3 year DFS for patients with QpCR was 98% vs. 89% without QpCR (hazard ratio 0.38 [95% Confidence Interval 0.09-0.84], P = 0.0134). HER2 status and response to FEC were independent predictors of QpCR. The overall clinical response was 75%; 85% of patients achieved breast conservation. Grade 3/4 neutropenia was the most common adverse event, observed in 44% and 35% of patients during FEC and docetaxel, respectively. Treatment related side effects were manageable; there were no treatment related fatalities. Conclusion FEC followed by docetaxel is an active and manageable preoperative regimen for women with early stage breast cancer. QpCR following preoperative chemotherapy predicts favorable DFS. HER2 overexpression and clinical response to FEC predict QpCR.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0167-6806
pubmed:author
pubmed:issnType
Print
pubmed:volume
110
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
531-9
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:17879158-Adult, pubmed-meshheading:17879158-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17879158-Breast Neoplasms, pubmed-meshheading:17879158-Cyclophosphamide, pubmed-meshheading:17879158-Disease-Free Survival, pubmed-meshheading:17879158-Epirubicin, pubmed-meshheading:17879158-Female, pubmed-meshheading:17879158-Fluorouracil, pubmed-meshheading:17879158-Humans, pubmed-meshheading:17879158-Kaplan-Meier Estimate, pubmed-meshheading:17879158-Mastectomy, Segmental, pubmed-meshheading:17879158-Middle Aged, pubmed-meshheading:17879158-Neoadjuvant Therapy, pubmed-meshheading:17879158-Preoperative Care, pubmed-meshheading:17879158-Receptor, erbB-2, pubmed-meshheading:17879158-Receptors, Estrogen, pubmed-meshheading:17879158-Receptors, Progesterone, pubmed-meshheading:17879158-Taxoids, pubmed-meshheading:17879158-Treatment Outcome
pubmed:year
2008
pubmed:articleTitle
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.
pubmed:affiliation
Department of Surgery (Breast Surgery), Graduate School of Faculty of Medicine, Kyoto University, 54 Shogoin-Kawara-cho, Sakyo-ku, Kyoto 606-8507, Japan. maktoi77@wa2.so-net.ne.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II